Name | PDK-IN-1 |
---|
Description | PDK-IN-1 (compound 7o) is a pyruvate dehydrogenase kinase (PDK) inhibitor. PDK-IN-1 shows IC50 values of 0.03 and 0.1 μM for PDK1 and HSP90, respectively. PDK-IN-1 targets PDH/PDK axis thus reducing efficiently the tumor mass[1]. |
---|---|
Related Catalog | |
Target |
IC50: 0.03 ± 0.005 μM (PDK1); 0.1 μM (HSP90)[1] |
In Vitro | PDK-IN-1 (compound 7o) 对 PSN-1 和 BxPC-3 胰腺细胞系显示出 2D 细胞毒活性,IC50 值分别为 0.1 ± 0.04 和 1.0 ± 0.2 μM。 PDK-IN-1 还显示出 3D 细胞毒活性,IC50 值分别为 3.3 ± 0.2 和 11.9 ± 1.1 μM[1]。 |
In Vivo | PDK-IN-1 (compound 7o) (20 mg/kg,腹腔注射,每天一次) 在减少肿瘤质量方面比顺铂 (HY-17394) 略微更有效[1]。 PDK-IN-1 显著降低 Lewis 肺癌 (LLC) 小鼠的 PDH 磷酸化[1]。 Animal Model: LLC-bearing C57BL mice[1] Dosage: 20 mg/kg Administration: IP, daily, days 7-14 Result: Reduced more tumor mass than cisplatin (HY-17394) (tumor inhibition by 86 and 84% for compound 7o and cisplatin, respectively). Induced a body weight loss much lower than that induced by cisplatin (HY-17394) and gemcitabine (HY-17026). |
References |
Molecular Formula | C20H16BrN7O |
---|---|
Molecular Weight | 450.29 |